In this issue:
- Novavax SARS-COV-2 vaccine in individuals with or without HIV-1
- Cabotegravir for preventing HIV-1 in women
- Kidney function in TDF-based oral PrEP users
- Interventions to re-engage patients with HIV lost to follow-up
- Rising rates of recent PrEP exposure among MSM newly diagnosed with HIV
- Evaluation of HIV treatment outcomes with reduced clinical encounters and ART refills
- Reasons for PrEP discontinuation
- Lung and HPV-associated cancers in HIV
- TB screening among HIV-positive inpatients
- COVID-19 hospitalisation outcomes in individuals with and without HIV
Please login below to download this issue (PDF)